1. Introduction {#sec1}
===============

Osteosarcoma (OS) is a common malignant bone tumor \[[@B1]\]. Despite curative resection of primary tumor, around 40% of OS patients develop isolated pulmonary metastases during the clinical course of OS \[[@B1]\]. There are limited novel therapeutic options, and the survival rate of patients with OS has not improved in the past decades. Better prognostic factors are important to improve the survival of patients with refractory OS.

Hypoxia-inducible factor 1 (HIF1) plays an important role in the response to low oxygen of cancer cells \[[@B2]--[@B4]\]. HIF1 help cancer cells adapt to hypoxia and promotes tumorigenesis \[[@B5]\]. HIF1 is overexpressed in many solid tumors, including OS, leading to unfavorable clinical outcome and poor survival \[[@B5]\]. Jumonji domain-containing protein 2B (JMJD2B) is a member of the JMJD2 family of histone demethylases and is directly regulated by HIF1 \[[@B6]\]. JMJD2B contains the catalytic JmjC domain to demethylate tri- and di-methylated lysine 9 (H3K9me3/2) on histone H3 \[[@B7]\]. JMJD2B is overexpressed in a variety of cancers including the liver, colon, lung, and gastric cancer as well as acute myeloid leukemia \[[@B8]--[@B11]\]. However, the association of the HIF1 and JMJD2B expressions and their significance in OS patients remain unclear. In this study, we aimed to explore the expression and prognostic significance of JMJD2B and HIF1 in OS.

2. Materials and Methods {#sec2}
========================

2.1. Subjects {#sec2.1}
-------------

This study was approved by the ethics committee of the Fourth Hospital of Hebei Medical University, and all subjects signed a written informed consent. OS samples were collected from 53 patients who visited the Fourth Hospital of Hebei Medical University between 2005 and 2013. Their histopathological and clinical characteristics were collected from medical records. No patients received radiotherapy or chemotherapy before surgery. The patients were grouped based on the age, gender, tumor size (\<5 cm and ≥5 cm), histological grade, Enneking stage (I-III), and neoadjuvant chemotherapy status.

2.2. Immunohistochemistry Analysis {#sec2.2}
----------------------------------

Immunohistochemical staining was performed on OS tissues using HIF1 antibodies (1 : 100; Abcam, USA) and JMJD2B antibodies (1 : 100; Abcam, USA) following the protocols described previously \[[@B12]\]. The number of positively stained cells in five randomly selected fields was analyzed by three pathologists blindly. The staining intensity was evaluated as follows: 0, no staining; 1, beige; 2, darker beige; and 3, tan. The staining extent was scored as follows: 0, 0% stained; 1, 1% to 25% stained; 2, 26% to 50% stained; and 3, 51% to 100% stained. The final scores were calculated by multiplying intensity score and extent score and judged as follows: 0 to 2, low staining (-/+); 3 to 5, medium staining (++); and 6 to 9, high staining (+++).

2.3. Statistical Analysis {#sec2.3}
-------------------------

Potential prognostic factors were analyzed by *χ*^2^ test. Correlations of histological and clinical variables were analyzed by Spearman\'s rho test. Univariate and multivariate analyses were conducted using Cox proportional hazards regression analysis. Survival curves were plotted by the Kaplan-Meier method. All statistical analyses were conducted using SPSS 25.0 software, and significance was set at *p* \< 0.05.

3. Results {#sec3}
==========

3.1. Characteristics of OS Patients {#sec3.1}
-----------------------------------

The characteristics of OS patient were summarized in [Table 1](#tab1){ref-type="table"}, their mean age was 35 years (range, 9-75 years), and median overall survival was 21 months (range, 2-91 months).

3.2. Correlation of HIF1 and JMJD2B Expressions with Clinicopathological Characteristics of OS Patients {#sec3.2}
-------------------------------------------------------------------------------------------------------

Correlation of the HIF1 and JMJD2B expressions with clinicopathological characteristics of OS patients was presented in [Table 1](#tab1){ref-type="table"}. Representative images of HIF1 and JMJD2B staining were shown in [Figure 1](#fig1){ref-type="fig"}. Both HIF1 and JMJD2B staining were primarily in the nucleus, but the staining scores varied from low to high among OS tissues. Specifically, the HIF1 expression was low in 17.0% (9/53), moderate in 28.3% (15/53), and high in 54.7% (29/53) of OS tissues, while the JMJD2B expression was low in 13.2% (7/53), moderate in 34.0% (18/53), and high in 52.8% (28/53) of OS tissues. Both HIF1 and JMJD2B showed significant association with distant metastasis (*p* \< 0.001), Enneking stage (*p* \< 0.001), and treatment with neoadjuvant chemotherapy (*p* \< 0.001) but showed no significant association with other clinicopathological parameters. Notably, we observed a significant positive correlation between the HIF1 and JMJD2B expressions (*p* \< 0.001) ([Table 2](#tab2){ref-type="table"}).

3.3. Correlation of HIF1 and JMJD2B Expressions with Poor Overall Survival of OS Patients {#sec3.3}
-----------------------------------------------------------------------------------------

[Table 3](#tab3){ref-type="table"} showed the results of univariate regression analysis of overall survival. The age, gender, tumor size, and histological grade were not significant predictors of overall survival, but distant metastasis (*p* \< 0.001), treatment with neoadjuvant chemotherapy (*p* \< 0.001), and higher Enneking stage (*p* \< 0.001) predicted shorter overall survival ([Figure 2](#fig2){ref-type="fig"}). Furthermore, higher HIF1 (*p* \< 0.001) and JMJD2B (*p* = 0.001) expressions showed significant association with shorter overall survival ([Table 3](#tab3){ref-type="table"}, [Figure 2](#fig2){ref-type="fig"}).

3.4. Higher JMJD2B Expression Predicted Poor Survival of OS Patients {#sec3.4}
--------------------------------------------------------------------

[Table 4](#tab4){ref-type="table"} showed the results of multivariate regression analysis of factors associated with overall survival revealed by univariate analysis. For multivariate analysis, only the JMJD2B expression (*p* \< 0.001), neoadjuvant chemotherapy (*p* \< 0.001), and Enneking stage (*p* \< 0.001) were identified as significant prognostic factors in OS patients. OS patients with high Enneking stage, history of neoadjuvant chemotherapy, and high JMJD2B expression had significantly increased risk of mortality (log-rank *p* \< 0.001; [Figure 2](#fig2){ref-type="fig"}).

4. Discussion {#sec4}
=============

To our knowledge, this is the first study to explore the expression pattern and prognostic significance of HIF1 and JMJD2B in OS patients. We found that higher HIF1 and JMJD2B levels showed a significant correlation with unfavorable clinical variables of OS patients. In addition, the HIF1 and JMJD2B expressions were positively correlated, and both HIF1 and JMJD2B were positively correlated with Enneking stage and distant metastasis. Moreover, univariate analysis showed a significant association of high HIF1 and JMJD2B expression levels with shorter overall survival in OS patients, and the JMJD2B expression was an independent prognostic indicator of OS patients. Overall, these results suggest that JMJD2B is a significant prognostic factor of OS.

HIF1 is overexpressed in a variety of solid tumors \[[@B13]\]. Moreover, our previous study indicated that HIF1 was overexpressed and possibly mediated hypoxia-induced autophagic activation in human OS tissues \[[@B14]\]. In this study, we confirmed that HIF1 was highly expressed in OS tissues and associated with poor survival, in agreement with previous findings that high HIF1 expression indicated poor outcomes in several types of cancer \[[@B15], [@B16]\].

JMJD2B demethylates methylation marks on H3K9 and H3K36, resulting in the activation of transcription \[[@B17]\]. HIF1 can regulate the transcription of JMJD2B due to the presence of hypoxia response elements in its promoter region \[[@B6]\]. JMJD2B also regulates cell proliferation and promotes bladder and lung cancer cell growth by modulating cyclin-dependent kinase 6 \[[@B18]--[@B20]\]. In addition, a previous study showed that significant upregulation of JMJD2B in tumor tissues promoted the expression of fibroblast growth factor 2 and became a risk factor for the development of OS \[[@B11]\]. In this study, we confirmed that JMJD2B could be a new prognostic marker of OS. However, the mechanisms underlying the regulation of HIF1 and JMJD2B in OS remain to be elucidated.

The present study has several limitations. First, immunohistochemical analysis is semiquantitative and needs further validation by real-time PCR. Second, our sample size was small, and our conclusion should be validated in larger samples.

In conclusion, HIF1 and JMJD2B are highly expressed in OS tissues and associated with unfavorable clinical characteristics and poor prognosis of OS patients. JMJD2B could a new clinical prognostic factor for OS patients.
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![Representative immunohistochemical staining of HIF1 and JMJD2B. (a) Low expression of HIF1 in OS. (b) Moderate expression of HIF1 in OS. (c) High expression of HIF1 in OS. (d) Low expression of JMJD2B in OS. (e) Moderate expression of JMJD2B in OS. (f) High expression of JMJD2B in OS. Cells with positive expression were stained brown.](ACP2020-2563208.001){#fig1}

![Overall survival curves for OS patients. Association of overall survival with (a) distant metastasis, (b) neoadjuvant chemotherapy, (c) Enneking stage, (d) HIF1 expression, and (e) JMJD2B expression. *p* values were determined by comparing survival distributions using the log-rank test.](ACP2020-2563208.002){#fig2}

###### 

Clinicopathological variables and HIF1 and JMJD2B expressions in OS patients.

  Characteristics                                                            HIF1                               JMJD2B                              
  ----------------------------- --------------------- ---------- ----------- ----------- ----------- ---------- ----------- ----------- ----------- ---------
  Gender                        Female                23         4 (17.4)    5 (21.7)    14 (60.9)   0.555      2 (8.7)     8 (34.8)    13 (56.5)   0.471
  Male                          30                    5 (16.7)   10 (33.3)   15 (50.0)               5 (16.7)   10 (33.3)   15 (50.0)               
                                                                                                                                                    
  Age                           \<20 years            22         5 (22.7)    5 (22.7)    12 (54.5)   0.752      9 (9.1)     9 (40.9)    11 (50.0)   0.953
  ≥20 years                     31                    4 (12.9)   10 (32.3)   17 (54.8)               5 (16.1)   9 (29.0)    17 (54.8)               
                                                                                                                                                    
  Tumor size                    \<5 cm                24         5 (20.8)    8(333)      11(458)     0\. 253    4 (167)     10 (41.7)   10 (41.7)   0.155
  ≥5 cm                         29                    4 (13.8)   7 (24.1)    18 (62.1)               3 (10.3)   8 (27.6)    18 (62.1)               
                                                                                                                                                    
  Histologic grade              Well differentiated   18         2 (11.1)    7 (38.9)    9 (50.0)    0\. 965    3 (16.7)    7 (38.9)    8 (44.4)    0.757
  Moderately differentiated     19                    3 (15.8)   5 (26.3)    11 (57.9)               3 (15.8)   5 (26.3)    11 (57.9)               
  Poorly differentiated         16                    4 (25.0)   3 (18.8)    9 (56.3)                1 (6.3)    6 (27.5)    9 (56.3)                
                                                                                                                                                    
  Distant metastasis^∗^         No                    30         9 (30.0)    13 (43.3)   8 (26.7)    \<0.001    7 (23.3)    16 (53.3)   7 (23.3)    \<0.001
  Yes                           23                    0 (0.0)    2 (8.7)     21 (91.3)               0 (0.0)    2 (8.7)     21 (91.3)               
                                                                                                                                                    
  Neoadjuvant chemotherapy^∗^   Yes                   32         8 (25.0)    15 (46.9)   9 (28.1)    \<0.001    7 (21.9)    16 (50.0)   9 (28.1)    \<0.001
  No                            21                    1 (4.8)    0 (0.0)     20 (95.2)               0 (0.0)    2 (9.5)     19 (90.5)               
                                                                                                                                                    
  Enneking stage^∗^             I                     10         8 (80.0)    2 (20.0)    0 (0.0)     \<0.001    6 (60.0)    3 (30.0)    1 (10.0)    \<0.001
  II                            18                    1 (5.6)    11 (61.1)   6 (33.3)                1 (5.6)    10 (55.6)   7 (38.9)                
  III                           25                    0 (0.0)    2 (8.0)     23 (54.7)               0 (0.0)    5 (20.0)    20 (80.0)               

The Spearman-rho test was used. ^∗^*p* \< 0.05.

###### 

Correlation of HIF1 and JMJD2B expressions.

  Characteristics                         JMJD2B                  *p*
  ----------------- ---------- ---------- ----------- ----------- ---------
                    Low        5 (55.6)   3 (33.3)    1 (11.1)    \<0.001
  HIFI              Moderate   2 (13.3)   11 (73.3)   2 (13.3)    
                    High       0 (0.0)    4 (13.8)    25 (86.2)   

The Spearman-rho test was used. ^∗^*p* \< 0.05.

###### 

Univariate Cox proportional regression analysis for the association of clinicopathological factors with overall survival of OS patients.

  Characteristics                                               HR                OS   *p*
  ----------------------------- --------------------- --------- ----------------- ---- ---------
  Gender                        Female                23        1                      0.214
  Male                          30                    0.677     0.366-1.252            
                                                                                       
  Age                           \<20 years            22        1                      0.865
  ≥20 years                     31                    0.948     0.511-1.759            
                                                                                       
  Tumor size                    \<5 cm                24        1                      0.492
  ≥5 cm                         29                    1.240     0.671-2.291            
                                                                                       
  Histologic grade              Well differentiated   18        1                      0.988
  Moderately differentiated     19                    0.998     0.478-2.080            
  Poorly differentiated         16                    1.053     0.499-1.053            
                                                                                       
  Distant metastasis^∗^         No                    30        1                      \<0.001
  Yes                           23                    5.311     2.403-11.736           
                                                                                       
  Neoadjuvant chemotherapy^∗^   Yes                   32        1                      0.002
  No                            21                    3.118     1.522-6.389            
                                                                                       
  Enneking stage^∗^             I                     10        1                      \<0.001
  II                            9                     12.605    2.643-60.109           
  III                           25                    51.909    9.949-270.831          
                                                                                       
  HIF1                          Low                   9         1                      \<0.001
  Moderate                      15                    10.589    2.230-50.275           
  High                          29                    44.344    8.280-237.493          
                                                                                       
  JMJD2B                        Low                   7         1                      \<0.001
  Moderate                      18                    20.018    2.470-162.224          
  High                          28                    110.895   11.857-1037.165        

OS: overall survival; HR: hazard ratio; 95% CI: 95% confidence interval. ^∗^*p* \< 0.05.

###### 

Multivariate Cox proportional regression analysis for the association of clinicopathological factors with overall survival of OS patients.

  Characteristics               OS                     
  ----------------------------- ------- -------------- -------
  Neoadjuvant chemotherapy^∗^   0.424   0.185-0.972    0.043
  Enneking stage^∗^             4.069   1.685-9.826    0.002
  JMJD2B^∗^                     4.002   1.492-10.735   0.006

OS: overall survival; HR: hazard ratio; 95% CI: 95% confidence interval. ^∗^*p* \< 0.05.
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